Microbiome insights may help predict immunotherapy benefit in kidney cancer
City of Hope researchers report that gut microbiome composition may influence how patients respond to immunotherapy combinations in metastatic renal cell carcinoma, pointing to a potential biomarker that could help guide treatment selection in the future.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.